EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated analysis identifies a palmitoylation-associated prognostic model (ACSM5/SKA3) for lung adenocarcinoma across multiple cohorts

Chaopeng Wu, Jinsong Wang, Yihan Liu, Zihan Ni, Yujie Zhan, Wanying Feng, Jia Feng, Min Peng

PeerJ · 29.04.2026 · 14 · e21160

DOI: 10.7717/peerj.21160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 29.04.2026. Verfasst von Chaopeng Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Lipoylation. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Hubei Science Foundation for Distinguished Young Scholars, The Interdisciplinary Innovative Talents Foundation of Renmin Hospital of Wuhan University, China Primary Health Care Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer and remains associated with poor prognosis despite therapeutic advances. Protein palmitoylation, particularly reversible S-palmitoylation, modulates oncogenic signaling, membrane localization, and immune checkpoint stability, but the prognostic landscape of palmitoylation-related genes (PRGs) in LUAD and their relationship with the tumor microenvironment are not well defined.

Methods

PRGs were curated from GeneCards and integrated with transcriptomic and clinical data from The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) cohort. Differential expression and univariate Cox analyses were performed to identify prognostic PRGs, which were then used for consensus clustering to define molecular subtypes and to construct a LASSO-Cox prognostic model. Associations between the risk score and functional pathways, genomic alterations, tumor mutational burden (TMB), tumor immune dysfunction and exclusion (TIDE) scores, and immune infiltration were evaluated. Three Gene Expression Omnibus (GEO) cohorts were used for external validation. Single-cell RNA sequencing (scRNA-seq) datasets and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of paired LUAD and adjacent tissues were used to assess cell type–associated expression and validate key genes.

Results

We identified 201 differentially expressed PRGs in LUAD and 15 genes significantly associated with overall survival, including the protective gene ACSM5 and the risk gene SKA3. PRG-based consensus clustering defined two molecular subtypes with distinct prognoses, differential enrichment of metabolism- versus proliferation-related pathways, and divergent immune microenvironment features. A two-gene signature comprising ACSM5 and SKA3 stratified patients into high- and low-risk groups in The Cancer Genome Atlas (TCGA) and three external cohorts, with time-dependent area under the curve (AUCs) of 0.717, 0.733, and 0.697 at 1, 3, and 5 years in TCGA and comparable performance in GEO validation cohorts (5-year AUC up to 0.778), indicating moderate discriminative performance. Low-risk patients generally showed higher stromal and immune scores and increased infiltration of multiple immune cell subsets, along with complex patterns in TMB and TIDE indices. Single-cell analyses indicated predominant expression of ACSM5 in macrophages and of SKA3 in proliferating CD8+ T cells and macrophages, and RT-qPCR confirmed downregulation of ACSM5 and upregulation of SKA3 in LUAD tissues.

Conclusion

This integrated analysis outlines a palmitoylation-associated molecular framework in LUAD and supports an ACSM5/SKA3 two-gene signature as a candidate prognostic tool that stratifies patient outcomes and reflects distinct metabolic, proliferative, and immune microenvironmental states, potentially providing a palmitoylation-associated basis for risk stratification and for the design of future mechanistic and therapeutic studies in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungLipoylationHumansPrognosisTumor MicroenvironmentGene Expression Regulation, NeoplasticFemaleBiomarkers, TumorMaleCohort Studies

Stichwörter der Autor:innen

ImmunotherapyLung adenocarcinomaPrognosisProtein palmitoylationTumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.

Förderung

  • The Hubei Science Foundation for Distinguished Young Scholars
  • The Interdisciplinary Innovative Talents Foundation of Renmin Hospital of Wuhan University
  • China Primary Health Care Foundation
  • Bethune Charitable Foundation
  • Wu Jieping Medical Foundation

Zitieren

APA

Wu, C., Wang, J., Liu, Y., Ni, Z., Zhan, Y., Feng, W., Feng, J., & Peng, M. (2026). Integrated analysis identifies a palmitoylation-associated prognostic model (ACSM5/SKA3) for lung adenocarcinoma across multiple cohorts. PeerJ, 14, e21160. https://doi.org/10.7717/peerj.21160

Vancouver

Wu C, Wang J, Liu Y, Ni Z, Zhan Y, Feng W, et al. Integrated analysis identifies a palmitoylation-associated prognostic model (ACSM5/SKA3) for lung adenocarcinoma across multiple cohorts. PeerJ. 2026;14:e21160. doi:10.7717/peerj.21160

BibTeX
@article{Wu2026,
  author = {Wu, Chaopeng and Wang, Jinsong and Liu, Yihan and Ni, Zihan and Zhan, Yujie and Feng, Wanying and Feng, Jia and Peng, Min},
  title = {Integrated analysis identifies a palmitoylation-associated prognostic model (ACSM5/SKA3) for lung adenocarcinoma across multiple cohorts},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21160},
  doi = {10.7717/peerj.21160}
}
Kostenlos starten →